| References |
1. Mera Y, Kawai T, Ogawa N, Odani N, Sasase T, Miyajima K, Ohta T, Kakutani M. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates lipid metabolism and attenuates atherosclerosis in hyperlipidemic animal models. J Pharmacol Sci. 2015 Nov;129(3):169-76. doi: 10.1016/j.jphs.2015.10.004. Epub 2015 Oct 20. PubMed PMID: 26598005. 2. Sakata S, Katsumi S, Mera Y, Kuroki Y, Nashida R, Kakutani M, Ohta T. Mechanism of action of hypoglycemic effects of an intestine-specific inhibitor of microsomal triglyceride transfer protein (MTP) in obese rats. J Pharmacol Sci. 2015 Jan;127(1):103-8. doi: 10.1016/j.jphs.2014.11.004. Epub 2014 Nov 22. PubMed PMID: 25704025. 3. Mera Y, Hata T, Ishii Y, Tomimoto D, Kawai T, Ohta T, Kakutani M. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, reduces food preference for fat. J Diabetes Res. 2014;2014:583752. doi: 10.1155/2014/583752. Epub 2014 May 15. PubMed PMID: 24959597; PubMed Central PMCID: PMC4052484. 4. Sakata S, Ito M, Mera Y, Sasase T, Yamamoto H, Kakutani M, Ohta T. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, improves hyperglycemia and dyslipidemia independent of suppression of food intake in diabetic rats. J Diabetes Res. 2014;2014:803832. doi: 10.1155/2014/803832. Epub 2014 May 7. PubMed PMID: 24895641; PubMed Central PMCID: PMC4033514. |
